<bill session="110" type="s" number="1887" updated="2016-06-29T09:33:29-04:00">
  <state datetime="2007-07-26">REFERRED</state>
  <status>
    <introduced datetime="2007-07-26"/>
  </status>
  <introduced datetime="2007-07-26"/>
  <titles>
    <title type="short" as="introduced">Medicare Access to Critical Medications Act of 2007</title>
    <title type="official" as="introduced">A bill to amend title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program.</title>
  </titles>
  <sponsor id="300090"/>
  <cosponsors>
    <cosponsor id="300060" joined="2007-07-26"/>
  </cosponsors>
  <actions>
    <action datetime="2007-07-26">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR S10156-10157"/>
    </action>
    <action datetime="2007-07-26" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
      <reference ref="CR S10157-10158" label="text of measure as introduced"/>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Convulsions"/>
    <term name="Drug therapy"/>
    <term name="Drugs"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Immunosuppressive drugs"/>
    <term name="Medicare"/>
    <term name="Mental depression"/>
    <term name="Prescription pricing"/>
    <term name="Social welfare"/>
    <term name="Virus diseases"/>
  </subjects>
  <amendments/>
  <summary>7/26/2007--Introduced.
Medicare Access to Critical Medications Act of 2007 - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to require prescription drug plan (PDP) formularies to include all or substantially all covered part D drugs in the therapeutic classes: (1) anticonvulsants; (2) antineoplastics; (3) antiretrovirals; (4) antidepressants; (5) antipsychotics; and (6) immunosuppressants.

Prohibits the application of a utilization management tool, such as prior authorization or step therapy, to such drugs in certain cases.

Prescribes requirements for treatment of such drugs when a determination or reconsideration is requested, as well as the treatment of appeals for such drugs.

Establishes data reporting requirements for such drug categories and classes.</summary>
</bill>
